Showing 1 - 14 results of 14 for search 'Byoung-Yong Shim', query time: 0.04s Refine Results
  1. 1
    Relationship between Systemic Inflammatory Markers, GLUT1 Expression, and Maximum 18F-Fluorodeoxyglucose Uptake in Non-Small Cell Lung Carcinoma and Their Prognostic Significance

    Relationship between Systemic Inflammatory Markers, GLUT1 Expression, and Maximum 18F-Fluorodeoxyglucose Uptake in Non-Small Cell Lung Carcinoma and Their Prognostic Significance by Sonya Youngju Park, Deog-Gon Cho, Byoung-Yong Shim, Uiju Cho

    Published 2023-03-01
    Get full text
    Article
  2. 2
    Efficacy of dabrafenib/trametinib in pancreatic ductal adenocarcinoma with BRAF NVTAP deletion: A case report

    Efficacy of dabrafenib/trametinib in pancreatic ductal adenocarcinoma with BRAF NVTAP deletion: A case report by Ji Eun Shin, Ho Jung An, Hyung Soon Park, Hyunho Kim, Byoung Yong Shim

    Published 2022-11-01
    Get full text
    Article
  3. 3
    Loss of Von Hippel–Lindau (<i>VHL</i>) Tumor Suppressor Gene Function: <i>VHL</i>–HIF Pathway and Advances in Treatments for Metastatic Renal Cell Carcinoma (RCC)

    Loss of Von Hippel–Lindau (<i>VHL</i>) Tumor Suppressor Gene Function: <i>VHL</i>–HIF Pathway and Advances in Treatments for Metastatic Renal Cell Carcinoma (RCC) by Hyunho Kim, Byoung Yong Shim, Seung-Ju Lee, Ji Youl Lee, Hyo-Jin Lee, In-Ho Kim

    Published 2021-09-01
    Get full text
    Article
  4. 4
    Association between Temporal Muscle Thickness and Overall Survival in Non-Small Cell Lung Cancer Patients with Brain Metastasis

    Association between Temporal Muscle Thickness and Overall Survival in Non-Small Cell Lung Cancer Patients with Brain Metastasis by Young Il Kim, Ja Young Shin, Seung Ho Yang, Hyun Ho Kim, Byoung Yong Shim, Stephen Ahn

    Published 2022-09-01
    Get full text
    Article
  5. 5
    Elevated serum substance P level as a predictive marker for moderately emetogenic chemotherapy‐induced nausea and vomiting: A prospective cohort study

    Elevated serum substance P level as a predictive marker for moderately emetogenic chemotherapy‐induced nausea and vomiting: A prospective cohort study by Hyung Soon Park, Hye Sung Won, Ho Jung An, Sung Shim Cho, Hyun Ho Kim, Der Sheng Sun, Yoon Ho Ko, Byoung Yong Shim

    Published 2021-02-01
    Get full text
    Article
  6. 6
    Somatic copy number alterations in gastric adenocarcinomas among Asian and Western patients.

    Somatic copy number alterations in gastric adenocarcinomas among Asian and Western patients. by Steven E Schumacher, Byoung Yong Shim, Giovanni Corso, Min-Hee Ryu, Yoon-Koo Kang, Franco Roviello, Gordon Saksena, Shouyong Peng, Ramesh A Shivdasani, Adam J Bass, Rameen Beroukhim

    Published 2017-01-01
    Get full text
    Article
  7. 7
    Plasma tumor mutation burden is associated with clinical benefit in patients with non-small cell lung cancer treated with anti-programmed death-1 monotherapy

    Plasma tumor mutation burden is associated with clinical benefit in patients with non-small cell lung cancer treated with anti-programmed death-1 monotherapy by Jii Bum Lee, Hyung Soon Park, Su Jin Choi, Seong Gu Heo, Ho Jung An, Hye Ryun Kim, Min Hee Hong, Sun Min Lim, Kyle Chang, Katie Quinn, Justin Odegaard, Byoung Yong Shim, Byoung Chul Cho

    Published 2022-12-01
    Get full text
    Article
  8. 8
    Significance of descriptive symptoms and signs and clinical parameters as predictors of neuropathic cancer pain.

    Significance of descriptive symptoms and signs and clinical parameters as predictors of neuropathic cancer pain. by Sun Kyung Baek, Sang Won Shin, Su-Jin Koh, Jung Han Kim, Hyo Jung Kim, Byoung Yong Shim, Seok Yun Kang, Sang Byung Bae, Hwan Jung Yun, Sun Jin Sym, Hye Sook Han, Ha Yeong Gil

    Published 2021-01-01
    Get full text
    Article
  9. 9
    The implications of clinical risk factors, CAR index, and compositional changes of immune cells on hyperprogressive disease in non-small cell lung cancer patients receiving immunotherapy

    The implications of clinical risk factors, CAR index, and compositional changes of immune cells on hyperprogressive disease in non-small cell lung cancer patients receiving immunot... by Seo Ree Kim, Sang Hoon Chun, Joo Ri Kim, Sang-Yeob Kim, Jun Young Seo, Chan Kwon Jung, Bo-Mi Gil, Jeong-Oh Kim, Yoon Ho Ko, In Sook Woo, Byoung Yong Shim, Sook-Hee Hong, Jin Hyoung Kang

    Published 2021-01-01
    Get full text
    Article
  10. 10
    363 Vactosertib and durvalumab as second or later line treatment for PD-L1 positive non-small cell lung cancer: interim result

    363 Vactosertib and durvalumab as second or later line treatment for PD-L1 positive non-small cell lung cancer: interim result by Byoung Chul Cho, Jin Kyung Lee, Jiyeon Ryu, Bitna Oh, Sunjin Hwang, Ki Baik Hahm, Seong-Jin Kim, Ki Hyeong Lee, Ji-Youn Han, Byoung Yong Shim, Hye Ryun Kim, Kyoung-Ho Pyo, Jae-Hwan Kim, Chung-Feng Xin

    Published 2020-11-01
    Article
  11. 11
    Clinical Outcomes of Upfront Primary Tumor Resection in Synchronous Unresectable Metastatic Colorectal Cancer

    Clinical Outcomes of Upfront Primary Tumor Resection in Synchronous Unresectable Metastatic Colorectal Cancer by Ji Eun Shin, Ho Jung An, Byoung Yong Shim, Hyunho Kim, Hyung Soon Park, Hyeon-Min Cho, Bong-Hyeon Kye, Ri Na Yoo, Ji-Yeon Moon, Sung Hwan Kim, Jonghoon Lee, Hyo Chun Lee, Ji-Han Jung, Kang-Moon Lee, Ji Min Lee

    Published 2023-10-01
    Get full text
    Article
  12. 12
    409 Trial in progress: a phase 2 study to assess the safety, efficacy of FLX475 combined with pembrolizumab in patients with advanced or metastatic gastric cancer

    409 Trial in progress: a phase 2 study to assess the safety, efficacy of FLX475 combined with pembrolizumab in patients with advanced or metastatic gastric cancer by Do-Youn Oh, Jeeyun Lee, Keun-Wook Lee, Hyun Cheol Chung, Michael Chisamore, Paul Rhee, Taewan Kim, Sang Cheul Oh, Min Hee Ryu, Jun-Eul Hwang, Jaeyong Cho, Dae Young Zang, Byoung Yong Shim, William Ho, Ji Yeong Won, Eunhye Baek, SeungJae Baek

    Published 2021-11-01
    Article
  13. 13
    710 Keynote-B59: dose escalation of a phase 1/2 first-in-human, open-label study of GI-101, a novel immunocytokine combining CD80-IL2v, in combination with pembrolizumab in advanced solid tumors

    710 Keynote-B59: dose escalation of a phase 1/2 first-in-human, open-label study of GI-101, a novel immunocytokine combining CD80-IL2v, in combination with pembrolizumab in advance... by John Powderly, Jae Lyun Lee, Jung-Yun Lee, Byoung Chul Cho, Kyoung-Ho Pyo, Soohyeon Lee, Dong Kim, Myoung Ho Jang, Byoung Yong Shim, Sang Joon Shin, Nari Yun, Mina Ham, Julia Cohen, Hyo Jin Lee, Kyoyoung Lee, Hyunjin Kang, Jea Hwan Kim, Mi hyun Kim

    Published 2023-11-01
    Article
  14. 14
    The impact of primary tumor location in patients with metastatic colorectal cancer: a Korean Cancer Study Group CO12-04 study

    The impact of primary tumor location in patients with metastatic colorectal cancer: a Korean Cancer Study Group CO12-04 study by Jae Ho Byun, Joong Bae Ahn, Sun Young Kim, Jung Hun Kang, Dae Young Zang, Seok Yun Kang, Myoung Joo Kang, Byoung Yong Shim, Sun Kyung Baek, Bong-Seog Kim, Kyung Hee Lee, Soon Il Lee, Sang-Hee Cho, Byeong Seok Sohn, Samyong Kim, In Gyu Hwang, Eun Mi Nam, Bong-Gun Seo, Sang Cheul Oh, Myung-Ah Lee, Sang-Cheol Lee, Ji Hyung Hong, Young Suk Park

    Published 2019-01-01
    Get full text
    Article

Search Tools: